Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 3/20 | 0.32 |
| ▸ | MAOB | P27338 | 3/20 | 0.32 |
| ▸ | ABL1 | P00519 | 2/20 | 0.31 |
| ▸ | PTGIR | P43119 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23845465 | 0.73 | KDM4E (0.41) | KDM4EGAAMAPTMEN1LMNA | |
| SCHEMBL30094532 | 0.72 | CHRNB2 (0.38) | MEN1KMT2ATDP1 | |
| SCHEMBL23833532 | 0.72 | CHRNB2 (0.38) | MEN1KMT2ATDP1 | |
| SCHEMBL24266137 | 0.71 | PTGIR (0.41) | MAPTMEN1LMNAKMT2ATDP1 | |
| SCHEMBL23845564 | 0.69 | GAA (0.45) | KDM4EGAAMAPTMEN1LMNA | |
| SCHEMBL23036866 | 0.69 | KDM4E (0.44) | KDM4EGAAMAPTMEN1LMNA | |
| SCHEMBL23832382 | 0.68 | DDB1 (0.42) | KDM4EGAAMAPTMEN1LMNA | |
| SCHEMBL23833567 | 0.66 | MAOA (0.43) | MAOAMAOBPTGIR | |
| SCHEMBL25354817 | 0.66 | KDM4E (0.47) | KDM4EGAAMAPTLMNAKMT2A | |
| SCHEMBL23833639 | 0.66 | CHRNA3 (0.40) | MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159489-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE | HIF1AN, EGLN3, PHF20 | KDM4E 69/4885GAA 3851/4885MAPT 4498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.